Breast cancer remains the most frequently diagnosed cancer and the leading cause of cancer mortality among women globally. While advances in hormone receptor-targeted therapies have improved outcomes for estrogen-receptor-positive (ER-positive) breast cancer, ER-negative subtypes, including triple-negative breast cancer, continue to show poor prognoses and limited treatment options. These cancers do not respond to hormonal therapies, making early detection and understanding of genetic predispositions critically important for preventive strategies and the development of novel targeted treatments.

The FANCM gene, previously recognized for its role in the Fanconi anemia DNA repair pathway, emerged as a gene of interest through this extensive whole exome sequencing analysis performed on a large cohort of Hispanic/Latina women diagnosed with ER-negative breast cancer. FANCM encodes a protein integral to maintaining genomic stability by orchestrating the repair of DNA interstrand cross-links and managing replication stress, processes that are fundamental to preventing malignant transformation. Mutations that impair FANCM’s function could therefore lead to a failure in DNA repair mechanisms, fostering the accumulation of genomic alterations that drive cancer development.

Importantly, this study leveraged one of the most comprehensive and ethnically diverse cohorts assembled to date for breast cancer genetic research. Hispanic/Latina populations have been notably understudied despite being the second largest ethnic group in the United States and carrying a disproportionate burden of aggressive breast cancer. By focusing on this cohort, the researchers filled a significant gap in understanding the genetic landscape that confers risk in minority populations often overlooked in precision medicine initiatives.

The discovery of FANCM as a susceptibility gene for ER-negative breast cancer in Hispanic/Latina women holds profound implications for the clinical management of breast cancer risk in this demographic. Current genetic screening panels typically emphasize genes like BRCA1 and BRCA2, which, while highly penetrant, are not the sole contributors to hereditary breast cancer. Including FANCM mutations could refine risk prediction models and enable the development of targeted screening programs, facilitating earlier detection and preventative interventions tailored to high-risk women in this population.

Technically, the identification of FANCM mutations was achieved through high-depth sequencing of the exome, allowing for precise detection of rare coding variants that might have otherwise been missed in studies focusing on more limited genomic regions. This approach is particularly advantageous when investigating complex diseases with heterogeneous etiology like breast cancer. By analyzing variants in the coding regions of thousands of genes simultaneously, the researchers pinpointed specific deleterious variants strongly enriched among patients with ER-negative breast cancer.

Moreover, functional assays performed in parallel validated the pathogenicity of these FANCM mutations. Using cellular models, the research team demonstrated how these variants compromised FANCM’s ability to resolve replication fork stalling and DNA damage, processes critical for genomic integrity. Cells harboring mutant FANCM exhibited increased sensitivity to DNA cross-linking agents and accumulated chromosomal abnormalities indicative of genomic instability, mechanistically establishing a causal link between FANCM dysfunction and tumorigenesis.

This study also highlights the evolutionary and population genetics aspects of FANCM variants. Certain mutations appeared at higher frequencies in Hispanic/Latina groups, suggesting a population-specific founder effect or genetic drift. These insights emphasize the necessity of including diverse ethnicities in genomic studies to capture population-specific risk alleles, which could otherwise remain hidden in studies dominated by European ancestry cohorts.

From a translational perspective, the findings open new avenues for personalized medicine. Given FANCM’s role in DNA repair, tumors arising from FANCM deficiency may exhibit unique vulnerabilities to DNA-damaging chemotherapy or agents that target compensatory repair pathways, such as PARP inhibitors. Clinical trials evaluating these therapeutic strategies could be prioritized for ER-negative breast cancer patients harboring FANCM mutations, potentially improving outcomes in an otherwise challenging patient subset.

The research also prompts a reevaluation of genetic counseling practices. Incorporating FANCM testing into multi-gene panels could alter risk assessment and management decisions for families with histories of ER-negative breast cancer, particularly in Hispanic/Latina women. Genetic counselors would need to interpret new variants of uncertain significance and provide guidance tailored to the nuanced risks associated with FANCM alterations.

Beyond breast cancer, FANCM mutations have been implicated in other malignancies and conditions marked by genomic instability. Therefore, this work may have broader implications for cancer biology, emphasizing the interconnectedness of DNA repair pathways across different tumor types and highlighting the potential for cross-cancer preventive strategies targeting these molecular vulnerabilities.

The timing of the study is especially propitious as advances in sequencing technology continue to drive down costs and increase accessibility, enabling more comprehensive genetic screening on a population scale. Incorporating genes like FANCM into next-generation sequencing panels could become standard practice, significantly advancing early detection and personalized prevention methods for high-risk individuals worldwide.

Despite these exciting developments, the authors caution that further research is necessary to fully elucidate the spectrum of FANCM mutations and their penetrance in diverse populations. Longitudinal studies and larger multi-ethnic cohorts will be instrumental in refining risk estimates and confirming the gene’s role across different breast cancer subtypes and ancestries.

Additionally, integrating genomic data with epidemiological and clinical information will enhance understanding of gene-environment interactions that modulate cancer risk. Sociodemographic factors, lifestyle, and reproductive history, when combined with FANCM status, could inform multifactorial models that more accurately predict individual susceptibility, moving closer to the goal of truly personalized cancer prevention.

This landmark study exemplifies how the intersection of advanced genomics, molecular biology, and population genetics can unravel the complexities of cancer susceptibility in historically underserved populations. It challenges the research community to prioritize inclusivity in genomic studies to ensure that precision oncology benefits all, not just a privileged few.

In conclusion, the identification of FANCM as a susceptibility gene for estrogen-receptor-negative breast cancer in Hispanic/Latina women marks a significant leap forward in breast cancer genomics. This discovery not only enriches the catalog of hereditary breast cancer genes but also paves the way for innovative prevention, diagnostic, and therapeutic strategies tailored to an ethnically diverse patient population enduring a disproportionate burden of aggressive cancer forms. As the field progresses, FANCM-focused research will undoubtedly play a pivotal role in shaping the future landscape of breast cancer care.

Subject of Research: The identification of FANCM gene mutations as a susceptibility factor for estrogen-receptor-negative breast cancer in Hispanic/Latina women through whole exome sequencing.

Article Title: Whole exome sequencing identifies FANCM as a susceptibility gene for estrogen-receptor-negative breast cancer in Hispanic/Latina women.

Article References:
Nierenberg, J.L., Adamson, A.W., Hu, D. et al. Whole exome sequencing identifies FANCM as a susceptibility gene for estrogen-receptor-negative breast cancer in Hispanic/Latina women. Nat Commun 16, 7816 (2025). https://doi.org/10.1038/s41467-025-60564-0

Image Credits: AI Generated

Polygenic risk scores are innovative genomic tools that assess an individual’s inherent susceptibility to breast cancer by aggregating the effects of numerous prevalent genetic variants. Through a sophisticated analysis of these genetic markers, PRSs offer a nuanced stratification of risk among women, significantly contributing to the early identification of those who are at elevated risk of developing breast cancer. By employing PRSs, healthcare providers can create tailored screening regimens and preventive measures uniquely suited to each individual, focusing on high-risk populations before the manifestation of clinical symptoms.

Despite the extensive research on polygenic risk scores and their growing prominence in predictive medicine discussions, a void existed in the form of standardized clinical guidance on their application in healthcare settings. The recent publication by this expert group seeks to fill this gap, defining actionable strategies that can be readily integrated into clinical practice. Dr. Peeter Padrik, the lead author and an oncologist at Tartu University Hospital, has emphasized the importance of this guidance as it empowers healthcare professionals to provide proactive and personalized preventative measures for women identified as being at higher risk.

The interplay between PRSs and existing genetic testing methodologies is intricately explored in the guidance. Professor Gareth Evans, who holds the position of Senior Author and is a Professor of Medical Genetics at the University of Manchester, points out that PRSs serve a complementary role in identifying risks among women lacking specific pathogenic genetic mutations, such as those found in BRCA1 or BRCA2 genes. The availability of this guidance introduces a structured approach for healthcare systems to utilize PRS information in a way that sharpens the focus and efficacy of breast cancer prevention and screening efforts.

In detailing the clinical applications of PRS testing, the guidance specifies relevant scenarios in which these evaluations can be employed. This includes the assessment of healthy women, regardless of whether they possess a family history of breast cancer, screening in hereditary cancer clinics, and the integration of PRSs into public health initiatives targeting population-wide risk assessments. Furthermore, the guidance illustrates how PRS results can be interpreted alongside other established risk factors through well-regarded prediction models, such as CanRisk and Tyrer–Cuzick, ultimately enhancing the precision of risk evaluations.

One of the hallmarks of this guidance is its alignment with existing national protocols and recommendations across different countries. It harmonizes PRS testing methods with established guidelines such as those from the UK’s National Institute for Health and Care Excellence (NICE), as well as practices observed in Germany, Sweden, Norway, Portugal, and Estonia. This global perspective ensures that the recommendations are applicable across diverse healthcare systems, promoting methodical and uniform implementation of PRS testing in preventive care.

The relevance and practical aspects of regulation are also key components incorporated into this guidance. The publication highlights the importance of adhering to compliance standards set by the EU In Vitro Diagnostic Medical Devices Regulation (IVDR), which governs the use of diagnostic tools across Europe. Additionally, the authors stress the necessity of ensuring equitable access to PRS testing and the performance of these protocols amongst various demographic and socioeconomic groups to guarantee that the benefits of personalized medicine in breast cancer risk assessment are universally experienced.

From the vantage point of clinical genetics, the inclusion of PRSs in risk assessment frameworks signifies an advancement in preventive healthcare. Dr. Sander Pajusalu, a clinical geneticist and Head of the Genetics and Personalised Medicine Clinic at Tartu University Hospital, has lauded the guidance for making genomic risk assessment a staple in preventive care. He asserts that polygenic risk scores extend the capacity for evaluating genetic predisposition to breast cancer, thereby facilitating the precise allocation of preventive strategies, such as mammography screening, to those in greatest need.

The guidance also addresses previously voiced concerns raised by the American College of Medical Genetics and Genomics (ACMG) regarding the lack of clinical frameworks governing the real-world use of PRSs. By outlining distinct clinical scenarios and laying the groundwork for practical applications, the authors provide a responsible and evidence-driven roadmap for the integration of polygenic risk scores in global healthcare systems. This clearly defined approach not only enhances the application of genomic tools in predicting disease risk but also encourages ongoing dialogue among clinicians regarding these emerging methodologies.

The collaborative effort behind the development of this guidance involved numerous researchers and clinicians engaged in the BRIGHT and AnteNOR research projects. These initiatives have been pivotal in advancing the understanding of PRS testing in breast cancer prevention, highlighting the commitment of interdisciplinary teams spanning the United Kingdom, Norway, Sweden, Portugal, and Estonia. The culmination of their combined expertise is reflected in the comprehensive nature of the guidance as it evolves the standard approach towards breast cancer risk assessment.

In conclusion, the introduction of clinical guidance for the practical implementation of polygenic risk scores in breast cancer prevention signifies a transformative leap for personalized medicine. This publication not only bridges a critical gap in existing healthcare frameworks but also fosters a proactive approach to disease prevention that promises to improve outcomes for women at risk of breast cancer. As the healthcare community embraces these recommendations, we may be on the cusp of a new era of personalized preventive care that fundamentally alters the trajectory of breast cancer management on a global scale.

Subject of Research: People
Article Title: Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores
News Publication Date: 21-Mar-2025
Web References: DOI Link
References: Cancers Journal
Image Credits: N/A

Keywords: breast cancer, polygenic risk scores, clinical guidance, personalized medicine, preventive care, genetic testing, healthcare integration, risk assessment